TIDAL Phase 2 trial

April 6, 2020April 6, 2020

ME-401 Put on FDA’s Fast Track for Previously Treated Follicular Lymphoma

News

The U.S. Food and Drug Administration (FDA) has granted fast track designation to MEI Pharma‘s investigational compound ME-401 for treating follicular lymphoma patients who received at least two prior therapies. A ... Read more

October 25, 2019

Durable Responses Seen to ME-401 in Advanced Follicular Lymphoma and CLL/SLL Patients in Ongoing Trial

News

MEI Pharma’s experimental compound ME-401 reduced tumor burden in 78% of patients with relapsed or refractory follicular lymphoma and in 89% of those with relapsed or refractory chronic lymphocytic leukemia or ... Read more

June 14, 2019

ME-401 Experimental Compound Reduces Tumor Burden in Follicular Lymphoma, Phase 1 Trial Shows

News

MEI Pharma‘s experimental compound ME-401 reduced tumor burden in 80% of patients with relapsed or refractory follicular lymphoma in a Phase 1 trial, the company said. Responses were comparable among ... Read more